

Ref. No: 2521
Date: 22nd April 2026
Subject: Use of Biologics in Secondary Care

REQUEST & REPOSE –

Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of Jan 2026 and end of Mar 2026?

Name of medicine	Number patients treated
1.1 Benralizumab (Fasenra)	0
1.2 Depemokimab (Exdensur)	0
1.3 Dupilumab (Dupixent)	135
1.4 Lebrikizumab (Ebglyss)	6
1.5 Mepolizumab (Nucala)	0
1.6 Omalizumab (Xolair)	20
1.7 Reslizumab (Cinqaero)	0
1.8 Tezepelumab (Tezspire)	0

Q2. How many patients were treated for severe asthma, COPD, CRwNP with the following medicines in the 3 months between the start of Jan 2026 and end of Mar 2026?

Name of medicine	Severe asthma (please include all types or references to asthma)	Chronic Obstructive Pulmonary Disease (COPD)	Chronic rhinosinusitis with nasal polyps (CRwNP)
2.1 Benralizumab (Fasenra)	0	0	0
2.2 Depemokimab (Exdensur)	0	0	0
2.3 Dupilumab (Dupixent)	0	0	0
2.4 Mepolizumab (Nucala)	0	0	0
2.5 Omalizumab (Xolair)	0	0	0
2.6 Reslizumab (Cinqaero)	0	0	0

2.7 Tezepelumab (Tezspire)	0	0	0
----------------------------	---	---	---

Q3. How many patients were treated for Atopic Dermatitis with the following medicines in the 3 months between the start of Jan 2026 and end of Mar 2026?

Name of medicine	Number of patients with Atopic Dermatitis
3.1 Dupilumab (Dupixent)	<5
3.2 Lebrikizumab (Ebglyss)	0

Q4. How many patients were treated by department in total, regardless of diagnosis, with the following medicines in the 3 months between the start of Jan 2026 and end of Mar 2026?

Name of medicine	Respiratory departments	Dermatology departments	Other departments
4.1 Benralizumab (Fasenra)	0	0	0
4.2 Depemokimab (Exdesur)	0	0	0
4.3 Dupilumab (Dupixent)	0	135	0
4.4 Lebrikizumab (Ebglyss)	0	6	0
4.5 Mepolizumab (Nucala)	0	0	0
4.6 Omalizumab (Xolair)	0	20	0
4.7 Reslizumab (Cinqaero)	0	0	0
4.8 Tezepelumab (Tezspire)	0	0	0

RESPONSE

Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of Jan 2026 and end of Mar 2026?

Name of medicine	Number patients treated
1.1 Benralizumab (Fasenra)	0
1.2 Depemokimab (Exdensur)	0
1.3 Dupilumab (Dupixent)	5
1.4 Lebrikizumab (Ebglyss)	0
1.5 Mepolizumab (Nucala)	0
1.6 Omalizumab (Xolair)	8
1.7 Reslizumab (Cinqaero)	0
1.8 Tezepelumab (Tezspire)	0

Q2. How many patients were treated for severe asthma, COPD, CRwNP with the following medicines in the 3 months between the start of Jan 2026 and end of Mar 2026?

Name of medicine	Severe asthma (please include all types or references to asthma)	Chronic Obstructive Pulmonary Disease (COPD)	Chronic rhinosinusitis with nasal polyps (CRwNP)
2.1 Benralizumab (Fasenra)	0	0	0
2.2 Depemokimab (Exdensur)	0	0	0
2.3 Dupilumab (Dupixent)	0	0	0
2.4 Mepolizumab (Nucala)	0	0	0
2.5 Omalizumab (Xolair)	0	0	0
2.6 Reslizumab (Cinqaero)	0	0	0
2.7 Tezepelumab (Tezspire)	0	0	0

Q3. How many patients were treated for Atopic Dermatitis with the following medicines in the 3 months between the start of Jan 2026 and end of Mar 2026?

Name of medicine	Number of patients with Atopic Dermatitis
3.1 Dupilumab (Dupixent)	<5
3.2 Lebrikizumab (Ebglyss)	0

Q4. How many patients were treated by department in total, regardless of diagnosis, with the following medicines in the 3 months between the start of Jan 2026 and end of Mar 2026?

Name of medicine	Respiratory departments	Dermatology departments	Other departments
4.1 Benralizumab (Fasenra)			
4.2 Depemokimab (Exdesur)			
4.3 Dupilumab (Dupixent)		5	
4.4 Lebrikizumab (Ebglyss)			
4.5 Mepolizumab (Nucala)			
4.6 Omalizumab (Xolair)	8		
4.7 Reslizumab (Cinqaero)			
4.8 Tezepelumab (Tezspire)			